AstraZeneca

STUDY REPORT SUMMARY

ASTRAZENECA MC Latvia

FINISHED PRODUCT: Atacand 16 mg
ACTIVE INGREDIENT: candesartan

Study No: NIS-CLV-ATA-2008/1
In-practice Evaluation of Atacand 16mg Antihypertensive Effect

Developmental phase: Non-Interventional Study
Study Completion Date: 01 February 2009
Date of Report: 18 June 2009

OBJECTIVES:

To prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure and the importance of administration of adequate doses.

Open-label, non-comparative, non-randomised, non-interventional study. The decision to initiate treatment precedes the decision to include the patient in the programme. The patients were managed according to usual clinical routines.
The analyses consisted of descriptive statistics and plots, illustrating different aspects of the daily use of Atacand 16mg.

RESULTS:

176 physicians evaluated 346 patients with essential hypertension during 2 visits at 4 weeks interval. Gender: 30% women, 70% men.
At inclusion: 12% Grade 1 (mild) hypertension patients (140-159/90-99 mmHg) and 88% Grade 2 (moderate) patients (160-179/100-109 mmHg).
75% patients reached the goal blood pressure (<140/<90 mmHg; for diabetes patients - 130/80 mm Hg).
The results suggest that the Atacand 16mg therapy is effective, easy to dose once daily and with good tolerability and compliance.